0001104659-23-096877.txt : 20230830 0001104659-23-096877.hdr.sgml : 20230830 20230830162245 ACCESSION NUMBER: 0001104659-23-096877 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230828 FILED AS OF DATE: 20230830 DATE AS OF CHANGE: 20230830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brenner Martin CENTRAL INDEX KEY: 0001770235 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 231225520 MAIL ADDRESS: STREET 1: C/O PFENEX INC. STREET 2: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 4 1 tm2325166-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-08-28 0 0001420720 iBio, Inc. IBIO 0001770235 Brenner Martin C/O IBIO, INC. 8800 HSC PARKWAY BRYAN TX 77807 0 1 0 0 See Remarks 0 Common Stock 2023-08-28 4 S 0 5011 0.3051 D 196865 D The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3051 to $0.3068 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Chief Executive Officer and Chief Scientific Officer /s/ Martin Brenner 2023-08-30